Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEXT Starts Full Discussions to Promote iPS Cell Research
January 28, 2008
- Gov't and Drug-Related Hepatitis Victims Agree on Settlement
January 28, 2008
- Korosho, MEXT, METI to Work Together to Promote iPS Cell Research
January 28, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 28, 2008
- Guidance to Promote Use of EDC Prepared by the JPMA
January 28, 2008
- TOPICS／PMDA Chief Executive Akira Miyajima Resigns
January 28, 2008
- Novartis to Step Back from Development of Vildagliptin in US
January 28, 2008
- Mundipharma to Focus on Pain and Cancer
January 28, 2008
- WG Proposes New Rule on Participation of Council Members with COI
January 28, 2008
- Takeda to Place Top Priority on Early Approval of SYR-322 and TAK-390MR: President Hasegawa
January 28, 2008
- REGULATORY NEWS IN BRIEF
January 28, 2008
- Kissei Licenses Treatment for ALI/ARDS from Pneuma Partners
January 28, 2008
- STATISTICS
January 28, 2008
- Merger with Ain Pharmaciez Is the Best Option for CFS: President Ishida
January 28, 2008
- OTC Drugs Help Cut Medical Expenditures: JSMI President Mr Miwa
January 28, 2008
- Why is Our Brand Underperforming against Expectations?
January 28, 2008
- JPA, JSMI to Regularly Exchange Opinions on Class 1 OTC Drugs
January 28, 2008
- TOPICS／J&J to Advertise Nicorette in Taxis
January 28, 2008
- TOPICS／T. Dooley Elected Chairman of Japan Intraocular Lens Association
January 28, 2008
- GENERICS NEWS IN BRIEF
January 21, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…